{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"12"}]}],"title":"Responders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"208"}]}],"title":"Non-responders"}],"denoms":[{"counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"220"}],"units":"Participants"}],"description":"BOR was defined as a complete response (CR) or partial response (PR) confirmed per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Participants who never received study treatment and treated participants without any post-baseline tumor assessments were considered as non-responders. CR: Disappearance of all target lesions, all non-target lesions and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to \\<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion and no new lesion.","groups":[{"description":"Participants received continuous oral doses of vemurafenib (RO5185426) 960 mg twice a day. Participants took four 240 mg tablets in the morning and four 240 mg tablets in the evening (960 mg twice a day for a total daily dose of 1920 mg).","id":"OG000","title":"Vemurafenib"},{"description":"Dacarbazine was administered intravenously 1000 mg/m˄2 up to 60 minutes on Day 1 of every 3 weeks (3 weeks was one cycle length).","id":"OG001","title":"Dacarbazine"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all ITT participants randomized by September 22, 2010 (at least 14 weeks prior to the clinical cutoff date of December 30, 2010). The 14-week interval was chosen as it was the minimum time needed to observe a confirmed overall response according to protocol-specified schedule for the first two tumor assessments.","reportingStatus":"POSTED","timeFrame":"From randomization (initiated January 2010) until December 30, 2010","title":"Participants With a Best Overall Response (BOR) of Complete Response or Partial Response","type":"SECONDARY","unitOfMeasure":"participants"}